7.2212

1.37% -0.0788

Biocryst Pharmaceuticals Inc (BCRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BCRX Giù? Forum Previsione

Precedente Chiudi:

$7.30

Aprire:

$7.3

Volume 24 ore:

539.92K

Relative Volume:

0.29

Capitalizzazione di mercato:

$1.51B

Reddito:

$331.41M

Utile/perdita netta:

$-226.54M

Rapporto P/E:

-5.777

EPS:

-1.25

Flusso di cassa netto:

$-97.31M

1 W Prestazione:

-3.36%

1M Prestazione:

-4.26%

6M Prestazione:

+12.15%

1 anno Prestazione:

+41.18%

Intervallo 1D:

$7.02

$7.31

Intervallo di 1 settimana:

$6.92

$7.52

Portata 52W:

$4.03

$8.88

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Nome

Biocryst Pharmaceuticals Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

919-859-1302

Indirizzo

4505 EMPEROR BOULEVARD, DURHAM, NC

Dipendente

531

Cinguettio

@biocrystpharma

Prossima data di guadagno

2024-11-04

Ultimi documenti SEC

BCRX's Discussions on Twitter

Confronta BCRX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BCRX	7.205	1.51B	331.41M	-226.54M	-97.31M	-1.25
VRTX	447.18	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.71	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	589.39	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.84	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.36	24.49B	3.30B	-501.07M	1.03B	11.54

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-09-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-08-04	Aggiornamento	Jefferies	Hold → Buy
2023-07-13	Aggiornamento	BofA Securities	Neutral → Buy
2023-02-22	Aggiornamento	Needham	Hold → Buy
2022-11-02	Aggiornamento	Evercore ISI	In-line → Outperform
2022-08-05	Downgrade	Evercore ISI	Outperform → In-line
2022-08-05	Downgrade	Oppenheimer	Outperform → Perform
2022-04-18	Downgrade	Barclays	Overweight → Equal Weight
2022-04-11	Downgrade	BofA Securities	Buy → Neutral
2021-12-10	Iniziato	Oppenheimer	Outperform
2021-08-06	Downgrade	Jefferies	Buy → Hold
2021-08-03	Iniziato	Cantor Fitzgerald	Overweight
2021-03-01	Iniziato	Cowen	Outperform
2020-09-29	Ripresa	JP Morgan	Overweight
2020-06-17	Iniziato	BTIG Research	Neutral
2020-05-05	Aggiornamento	Barclays	Equal Weight → Overweight
2019-11-15	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2018-11-16	Ripresa	Piper Jaffray	Overweight
2018-08-08	Ripresa	JP Morgan	Overweight
2018-07-17	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-06-22	Iniziato	Seaport Global Securities	Neutral
2018-01-02	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2017-12-20	Iniziato	Barclays	Equal Weight
2017-09-15	Iniziato	RBC Capital Mkts	Sector Perform
2017-09-06	Aggiornamento	JP Morgan	Neutral → Overweight
2017-09-06	Aggiornamento	Jefferies	Hold → Buy
2017-02-16	Iniziato	Ladenburg Thalmann	Buy
2016-08-12	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-08-04	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Reiterato	FBR Capital	Outperform
2016-02-09	Downgrade	JP Morgan	Overweight → Neutral
2016-02-09	Downgrade	Needham	Buy → Hold

Mostra tutto

Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie

07:45 AM

Hereditary Angioedema Therapeutics Market Report Outlines - openPR

07:45 AM

Nov 20, 2024

Cystinosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, - openPR

Nov 20, 2024

Nov 19, 2024

Counterweight Ventures LLC Increases Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat

Nov 19, 2024

Nov 18, 2024

Primary Hyperoxaluria Drug Market SWOT Analysis by Leading Key Players: Pfizer, Novartis, BioCryst - openPR

Nov 18, 2024

Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreases By 7.5% - MarketBeat

Nov 18, 2024

BioCryst Launches ORLADEYO® (berotralstat) in Ireland - GlobeNewswire

Nov 18, 2024

BioCryst's ORLADEYO Becomes First Oral HAE Treatment Approved in Ireland | BCRX Stock News - StockTitan

Nov 18, 2024

Nov 17, 2024

(BCRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 17, 2024

Nov 13, 2024

Avian influenza Treatment Market Growth Trends: Regional - openPR

Nov 13, 2024

Nov 12, 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by GSA Capital Partners LLP - MarketBeat

Nov 12, 2024

Nov 09, 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 09, 2024

Nov 07, 2024

Vanguard Group Inc's Strategic Acquisition in BioCryst Pharmaceu - GuruFocus.com

Nov 07, 2024

HC Wainwright Has Optimistic Outlook of BCRX Q4 Earnings - MarketBeat

Nov 07, 2024

Nov 06, 2024

Ionis Looks Ahead To Commercializing Its Own Products - Citeline News & Insights

Nov 06, 2024

Objective long/short (BCRX) Report - Stock Traders Daily

Nov 06, 2024

BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire

Nov 06, 2024

BioCryst (BCRX) to Present at Three Major Healthcare Investor Conferences | BCRX Stock News - StockTitan

Nov 06, 2024

Nov 05, 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 05, 2024

BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Earnings Results, Hits Estimates - MarketBeat

Nov 05, 2024

BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat

Nov 05, 2024

Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat

Nov 05, 2024

BCRXBioCryst Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan

Nov 05, 2024

Earnings call: BioCryst Pharmaceuticals reports strong Q3 growth - Investing.com India

Nov 05, 2024

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 05, 2024

BioCryst Announces Strong Q3 2024 Revenue Growth - Yahoo Finance

Nov 05, 2024

BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026 - Marketscreener.com

Nov 05, 2024

BioCryst Awards Key Talent with $8.01 Stock Options, RSU Compensation Package | BCRX Stock News - StockTitan

Nov 05, 2024

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Nov 05, 2024